Multiple studies have demonstrated that ncRNAs can impact the efficacy of osimertinib treatment in NSCLC with EGFR mutations by regulating cancer cell apoptosis and pyroptosis, either individually or in combination. Here, EGFR is linked to non-small cell lung carcinoma.